A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer
Treatment
Phase 2 treatment study for recurrent endometrial cancer
Clinicaltrials.gov identifier:NCT04486352
Study Contact Information:
For additional information, please contact by phone at (617) 732-8727
or by email.
About the Study
This study is to test the safety and effectiveness of different kinds of with or without atezolizumab (or Tecentriq) in individuals with recurrent . Participants will be placed into study groups based on their tumor.
This Study is Open To:
Women 18 years or older who:
- have a life expectancy of more than 12 weeks
- have recovered from effects of recent chemotherapy, radiation, or surgery
- have a tumor sample
- have recurrent which has recurred after at least one but no more than two prior forms of therapy
This Study is NOT Open To:
Patients with:
- other invasive cancers within the last five years
- an active or history of autoimmune disease or immune deficiency
- active tuberculosis
- have significant heart disease
- have received a live vaccine in the last four weeks
- have had a severe infection within the last four weeks
- have had prior bone marrow transplant or antibiotic medication through the vein within the past four weeks
- More exclusion criteria found on clinicaltrials.gov
What the Study Involves
The study involves 6 groups:
Group 1:
Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and bevacizumab (Avastin) intravenously every two weeks of the 28-day cycle.
Group 2:
Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and Ipatasertib orally once daily for 21 days of the 28-day cycle.
Group 3:
Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and (or ) orally once daily for every day of the 28-day cycle.
Group 4:
Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and Trastuzumab emtansine (or Kadcyla) intravenously on Day 1 of each 21-day cycle.
Group 5:
Participants will receive Tecentriq intravenously (injected into the vein) on Day 1 of each cycle and Tiragolumab intravenously on Day 1 of each 28-day cycle.
Group 6:
Participants will receive Inavolisib and Lentrozole (or Femara) orally once daily for every day of the 28-day cycle.
Study Contact Information:
For additional information, please contact by phone at (617) 732-8727
or by email.
Locations:
Oklahoma
City: Oklahoma City RECRUITING
Facility: University of Oklahoma Health Stephenson Cancer Center
Contact Info:
Debra Richardson, MD
Treatment
Phase 2 treatment study for recurrent endometrial cancer
Clinicaltrials.gov identifier:NCT04486352
Study Contact Information:
For additional information, please contact by phone at (617) 732-8727
or by email.